Is LadRx Corp (LADX) Halal?

NYSE Healthcare United States $49,509
✗ NOT HALAL
Confidence: 83/100
LadRx Corp (LADX) is Not Halal under AAOIFI Standard 21. While the debt ratio of 0.0% is acceptable, the cash and interest-bearing securities ratio of 1534.6% exceeds the 30% threshold. LadRx Corp operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
1534.6%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 0.0%
/ 33%
1534.6%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 0.0%
/ 33%
90.5%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
1534.6%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 0.0%
/ 33%
90.5%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-5.04
P/B Ratio
-0.0
EV/EBITDA
0.1
EV: -$181,698
Revenue
$0
Beta
0.5
Low volatility
Current Ratio
0.1

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Assets (ROA) -176.9%

Cash Flow & Balance Sheet

Operating Cash Flow-$1M
Free Cash Flow-$1M
Total Debt$0
Current Ratio0.1
Total Assets$839,512

Price & Trading

Last Close$0.10
50-Day MA$0.08
200-Day MA$0.70
Avg Volume145
Beta0.5
52-Week Range
$0.01
$2.20

About LadRx Corp (LADX)

CEO
Mr. John Y. Caloz CPA
Employees
2
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NYSE
Market Cap
$49,509
Currency
USD

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is LadRx Corp (LADX) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), LadRx Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is LadRx Corp's debt ratio?

LadRx Corp's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are LadRx Corp's key financial metrics?

LadRx Corp has a market capitalization of $49,509.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.